Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot

View ORCID ProfileSimon P Keam, Heloise Halse, Thu Nguyen, Minyu Wang, Nicolas Van Kooten Losio, Catherine Mitchell, Franco Caramia, David J Byrne, Sue Haupt, Georgina Ryland, Phillip K Darcy, Shahneen Sandhu, Piers Blombery, Ygal Haupt, Scott G Williams, Paul J Neeson
doi: https://doi.org/10.1101/2020.03.02.20030346
Simon P Keam
1Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
2Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia
4Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Simon P Keam
Heloise Halse
2Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thu Nguyen
2Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minyu Wang
2Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Van Kooten Losio
2Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Mitchell
3Pathology Department, Peter MacCallum Cancer Centre, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franco Caramia
1Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J Byrne
3Pathology Department, Peter MacCallum Cancer Centre, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sue Haupt
1Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
4Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georgina Ryland
3Pathology Department, Peter MacCallum Cancer Centre, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Phillip K Darcy
2Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia
4Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shahneen Sandhu
5Genitourinary Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piers Blombery
3Pathology Department, Peter MacCallum Cancer Centre, Melbourne, Australia
4Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ygal Haupt
1Tumor Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
4Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia
6Department of Biochemistry and Molecular Biology, Monash University, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott G Williams
7Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul J Neeson
2Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia
4Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: paul.neeson{at}petermac.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Prostate cancer (PCa) has a profoundly immunosuppressive microenvironment, we hypothesized that radiation therapy would break this immune suppression. To investigate this, we performed high-throughput immune cell subset analysis, and gene expression profiling of pre-versus post-radiation tissue in a cohort of patients with localized disease that received high dose-rate brachytherapy (HDRBT). We resolved tumor and non-tumor zones in our spatial analysis to explore what drives the immunological response. Nanostring immune profiling revealed numerous immune checkpoint molecules were stimulated in response to HDRBT (e.g. B7-H3, CTLA4, PDL1 and PDL2). A published 16-gene tumor inflammation signature (TIS) gene profiling of immune activation states (high:hot, intermediate and low:cold) showed that most tissues possessed a low TIS pre-HDRBT. Crucially, HDRBT converted 80% of these ‘cold’-phenotype tumors into an ‘intermediate’ or ‘hot’ class. We used digital spatial profiling to show these HDRBT-induced changes in prostate TIS scores were derived from the non-tumor regions. Furthermore, these changes in TIS were also associated with pervasive changes in immune cell density and spatial relationships – in particularly between T cell subsets and antigen presenting cells. We identified increased density of CD4+ FOXP3+ T cells, CD68+ macrophages and CD68+ CD11c+ dendritic cells in response to HDRBT. The only subset change in tumor zones was PDL1+ macrophages. While these immune responses were heterogeneous, HDRBT induced significant changes in immune cell associations, including a gained T cell and HMWCK+ PDL1+ interaction in tumor zones. In conclusion, we showed HDRBT has a clear impact in converting “cold” prostate tumors into more immunologically activated “hot” tissues, with accompanying spatially-organized immune infiltrates and signaling changes. Understanding and potentially harnessing these changes will have widespread implications for the future treatment of localized PCa and the possible use of combination immunotherapies.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by the PeterMac Foundation, the Victorian Cancer Agency, a Prostate Cancer Foundation USA (Creativity award), Cancer Council Victoria (Grant-In-Aid) and an NHMRC Program Grant.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Denotes shared first author

  • ↵# Denotes shared senior author

  • Conflict of Interest Statement: The authors have no conflicts of interest to declare.

  • Funding This study was funded by the PeterMac Foundation, the Victorian Cancer Agency, a Prostate Cancer Foundation USA (Creativity award), Cancer Council Victoria (Grant-In-Aid) and an NHMRC Program Grant.

  • Availability of data and materials The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request

Data Availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request

  • List of Abbreviations

    PCa
    Prostate cancer
    HDRBT
    High dose-rate brachytherapy
    TIS
    Tumor inflammation signature
    EBRT
    External beam radiation therapy
    RT
    Radiation therapy
    IHC
    Immunohistochemistry
    mIHC
    Multiplexed immunohistochemistry
    IC
    Immune checkpoint
    ADT
    Androgen deprivation therapy
    PMCC
    Peter MacCallum Cancer Centre
    MRI
    Magnetic resonance imaging
    PET
    Positron emission tomography
    ISUP
    International Society of Urological Pathology
    FFPE
    Formalin-fixed paraffin-embedded
    GG
    Gleason grade
    HIER
    Heat-induced epitope retrieval
    DSP
    Digital spatial profiling
    ROI
    Region of interest
    RB
    RadBank
    GEP
    Gene expression profile
    IO
    Immuno Oncology
    APC
    Antigen presenting cell
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted March 06, 2020.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot
    Simon P Keam, Heloise Halse, Thu Nguyen, Minyu Wang, Nicolas Van Kooten Losio, Catherine Mitchell, Franco Caramia, David J Byrne, Sue Haupt, Georgina Ryland, Phillip K Darcy, Shahneen Sandhu, Piers Blombery, Ygal Haupt, Scott G Williams, Paul J Neeson
    medRxiv 2020.03.02.20030346; doi: https://doi.org/10.1101/2020.03.02.20030346
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot
    Simon P Keam, Heloise Halse, Thu Nguyen, Minyu Wang, Nicolas Van Kooten Losio, Catherine Mitchell, Franco Caramia, David J Byrne, Sue Haupt, Georgina Ryland, Phillip K Darcy, Shahneen Sandhu, Piers Blombery, Ygal Haupt, Scott G Williams, Paul J Neeson
    medRxiv 2020.03.02.20030346; doi: https://doi.org/10.1101/2020.03.02.20030346

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Oncology
    Subject Areas
    All Articles
    • Addiction Medicine (427)
    • Allergy and Immunology (753)
    • Anesthesia (220)
    • Cardiovascular Medicine (3281)
    • Dentistry and Oral Medicine (362)
    • Dermatology (274)
    • Emergency Medicine (478)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
    • Epidemiology (13340)
    • Forensic Medicine (19)
    • Gastroenterology (897)
    • Genetic and Genomic Medicine (5131)
    • Geriatric Medicine (479)
    • Health Economics (781)
    • Health Informatics (3253)
    • Health Policy (1138)
    • Health Systems and Quality Improvement (1189)
    • Hematology (427)
    • HIV/AIDS (1014)
    • Infectious Diseases (except HIV/AIDS) (14613)
    • Intensive Care and Critical Care Medicine (910)
    • Medical Education (475)
    • Medical Ethics (126)
    • Nephrology (522)
    • Neurology (4901)
    • Nursing (261)
    • Nutrition (725)
    • Obstetrics and Gynecology (880)
    • Occupational and Environmental Health (795)
    • Oncology (2516)
    • Ophthalmology (722)
    • Orthopedics (280)
    • Otolaryngology (346)
    • Pain Medicine (323)
    • Palliative Medicine (90)
    • Pathology (540)
    • Pediatrics (1298)
    • Pharmacology and Therapeutics (548)
    • Primary Care Research (554)
    • Psychiatry and Clinical Psychology (4193)
    • Public and Global Health (7482)
    • Radiology and Imaging (1702)
    • Rehabilitation Medicine and Physical Therapy (1010)
    • Respiratory Medicine (979)
    • Rheumatology (478)
    • Sexual and Reproductive Health (495)
    • Sports Medicine (424)
    • Surgery (546)
    • Toxicology (71)
    • Transplantation (235)
    • Urology (203)